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Role of AT-1 receptor in regulation of vascular MCP-1, IL-6,
PAI-1, MAP kinase, and matrix expressions in obesity.
Background. Metabolic syndrome has emerged as the major
cause of atherosclerosis. The associated atherosclerosis is ac-
companied by and, in part, due to inflammation. In an attempt
to explore the molecular sources of vascular inflammation and
possible involvement of renin-angiotensin system, we stud-
ied obese Zucker rats, which exhibit all features of metabolic
syndrome.
Methods. Seven-week-old male obese Zucker rats were ran-
domized to losartan-treated (100 mg/L drinking H2O) and un-
treated groups. Lean Zucker rats served as controls. After four
months, aortas were obtained and processed for various deter-
minations by reverse transcription-polymerase chain reaction
(RT-PCR) and Western blot and immunohistochemical analy-
sis for collagen type IV.
Results. Compared to the lean controls, obese Zucker rats
showed significant increases in collagen staining, as well as
expressions of collagen, fibronectin, plasminogen activator
inhibitor-1, and two major proinflammatory mediators (i.e.,
interleukin-6 and monocyte chemoattractant protein-1). This
was associated with significant increases in p38 and ERK1/2
mitogen activated protein kinase activities, as well as marked
up-regulation of angiotensin II type 1 receptor (AT-1R) mRNA
expression. These abnormalities were prevented by administra-
tion of the AT-1R blocker (ARB).
Conclusion. The untreated obese Zucker rats exhibit in-
creased matrix protein accumulation in the aorta and marked
up-regulations of proinflammatory and profibrotic pathways.
These abnormalities are associated with up-regulation of AT-1R
and are prevented by AT-1R blockade pointing to the potential
role of AT-1R activation.
Atherosclerosis is the primary cause of coronary dis-
ease, stroke, ischemic nephropathy, and peripheral vas-
cular disease and, as such, represents the main cause
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of morbidity and mortality in the industrialized soci-
eties. Metabolic syndrome, otherwise known as syndrome
X or insulin resistance syndrome is the principal cause
of diabetes and atherosclerosis in the developed coun-
tries [1, 2]. The syndrome is defined as an aggregation
of several proatherogenic conditions, including insulin
resistance, hyperinsulinemia, and some combination of
dyslipidemia, obesity, endothelial dysfunction, hyperco-
agulability, and hypertension [3–7]. In addition, inflam-
mation is frequently present and plays a major role in
atherogenesis and cardiovascular disease in metabolic
syndrome [8–10].
Increasing evidence suggests that insulin resistance
causes inflammation and inflammation promotes insulin
resistance [11–13]. Given the central role of inflamma-
tion in the pathogenesis of atherosclerosis, the associated
inflammation must be involved in the atherogenic diathe-
sis in the metabolic syndrome. Inflammatory chemokines,
particularly monocyte chemoattractant protein-1 (MCP-
1), and cytokines participate in macrophage recruitment,
whereas metaloproteinase inhibitors, particularly plas-
minogen activator inhibitor-1 (PAI-1) and activated mito-
gen activated protein kinases (MAPK), promote matrix
accumulation, cell migration, and proliferation, events
that are critical in atherogenesis. Production of sev-
eral cytokines, including tumor necrosis factor-alpha and
interleukin-6 (IL-6) is increased in obesity and insulin
resistance [11].
It is of note that (renin)-angiotensin system (RAS)
activity is augmented in the metabolic syndrome [14],
and blockade of the RAS ameliorates insulin resistance
and prevents/delays onset of type 2 diabetes [15–20].
Moreover, activation of angiotensin II type 1 receptor
(AT1R) by angiotensin II promotes inflammation, oxida-
tive stress, and cardiovascular remodeling [21, 22]. Thus,
AT-1 receptor activation may be involved in inflamma-
tion and atherogenesis in metabolic syndrome.
Metabolic syndrome is frequently caused by envi-
ronmental conditions, notably sedentary lifestyle, excess
caloric intake, and high-fat, high-refined sugar diet, as
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well as a variety of acquired and hereditary disorders.
Autosomal-recessive mutation of gene, encoding leptin
receptor in the obese Zucker rat results in hyperpha-
gia and metabolic syndrome, which manifests as obesity,
insulin resistance, hyperinsulinemia, impaired glucose
tolerance, and hyperlipidemia [23–26]. Obese Zucker
rats are commonly used as a model to study metabolic
syndrome.
In view of the association of metabolic syndrome with
increased RAS activity, inflammation, and vascular dis-
ease, we hypothesized that the pathway involved in in-
flammation and remodeling may be activated in the aorta
of the obese Zucker rats. We further considered that long-
term blockade of RAS may reverse dysregulation of these
pathways. Accordingly, we measured AT1R, MCP-1, IL-
6, PAI-1, matrix proteins (collagen and fibronectin), as
well as activities of p38 and ERK1/2 MAPK in the aor-
tas of the obese and lean Zucker rats. We further ex-




Antibodies for phosphospecific and nonphospho-p38
and -ERK1/2 MAPK were from Cell Signaling (Beverly,
MA, USA); collagen a (IV) antibody was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); Supersig-
nal chemiluminescence reagent from Pierce (Rockford,
IL, USA); Relative multiplex reverse transcription-
polymerase chain reaction (RT-PCR) kits and primers
for Quantum RNA 18S internal standards were from
Ambion, Inc. (Austin, TX, USA); RNA-STAT60 reagent
was from Tel-Test (Friendswood, TX, USA). Losartan
(ARB) was obtained from Merck Co. (Westpoint, PA,
USA).
Animals and experimental design
All animal studies were conducted under a protocol
approved by the Animal Care and Use Committee of
the University of California, Irvine. Seven-week-old male
lean Zucker rats (N = 6) and male obese Zucker rats (N =
12) were used in this study. Obese animals were further
randomized into two groups of six rats each. One group of
obese Zucker rats was administered losartan in the drink-
ing water (100 mg/L) for four months. Under general
anesthesia, the rats were sacrificed by exsanguinations
using cardiac puncture. Aortas were removed and stored
at −70◦C for further study. Additional specimens were
fixed in 10% formalin for histologic evaluation. Tail arte-
rial pressure, serum glucose, cholesterol, and triglyceride
concentrations were determined by standard methods.
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Relative and competitive RT-PCR
Total RNA was isolated using RNA-STAT60 reagent
according to the manufacturer’s instructions. cDNA
was synthesized with 1 lg of RNA using murine
leukemia virus reverse transcriptase and random hex-
amers. Primers for the 18S ribosomal RNA (489-bp or
324-bp) were included in each reaction as an internal con-
trol. The primers used are summarized in Table 1. Rel-
ative reverse transcription-polymerase chain reactions
(RT-PCRs) were performed as described previously [25].
For AT1R mRNA expression, we used a quantita-
tive competitive RT-PCR method as described previously
[26]. The AT1R competitor cDNA (212 bp) used as inter-
nal standard was designed to contain the same base pair
sequence as the target cDNA that would allow efficient
priming, but had a portion deleted so that the com-
petitor PCR-generated fragment could be easily distin-
guished electrophoretically by size. Band densities were
analyzed by laser densitometry (Bio-Rad Laboratories,
Hercules, CA, USA). The RT-PCR products were sepa-
rated by electrophoresis and competitive PCR measure-
ments were expressed as a ratio of the wild-type divided
by the mutant band densities as described previously [27].
Immunohistochemical studies
Aorta tissues for immunohistochemical staining were
fixed in 10% neutral buffered formalin and paraffin em-
bedded by standard techniques, and 5 micron sections
were utilized. Collagen a (IV) staining was performed
using a commercial kit (Dako Corporation, Carpinteria,
CA, USA) according to the manufacturer’s instructions
and as described previously [28].
Western blot analysis
Tissue samples were lysed in sodium dodecyl sulfate
(SDS) sample buffer [2% SDS, 10 mmol/L Tris-HCl,






























Fig. 1. AT1R expression in lean Zucker rats,
obese Zucker rats, and obese Zucker rats
treated with ARB for four months. AT1R
mRNA expression in the aorta was de-
termined by competitive RT-PCR. A fixed
amount of AT1R wild-type cDNA and fixed
amount of AT1R competitor cDNA were
used (A). Data are shown as mean ± SEM
from six rats in each group. ∗P < 0.01 vs. lean
Zucker rats (B).
pH 6.8, 10% (vol/vol) glycerol]. Lysates were centrifuged
at 12,000 rpm for 15 minutes at 4◦C and the supernatant
stored at −70◦C. Fifty micrograms of protein per lane
were separated on a 10% SDS-PAGE gels (Bio-Rad
Laboratories), transferred onto a nitrocellulose mem-
brane and immunoblotted with antibodies to phospho-
p38 (1:500), phospho-ERK1/2 (1:500). The blots were
stripped and then reprobed with an antibody to total p38
(1:1000) or total ERK1/2 (1:1000). Immunoblots were
scanned using GS-800 densitometer and protein bands
quantitated with Quantitation One software (Bio-Rad
Laboratories).
Statistical analyses
Data are expressed as mean ± SEM from multiple
experiments. ANOVA with Tukey’s post tests for mul-
tiple groups were employed in statistical evaluation of
the data using PRISM software (GraphPad, San Diego,




Compared with the lean Zucker rats the untreated
obese Zucker rats showed significant increases in body
weight (688 ± 11 g vs. 423 ± 8 g, P < 0.01) and plasma
concentrations of cholesterol (164 ± 12 vs. 79 ± 5 mg/dL,
P < 0.01) and triglyceride (549 ± 105 vs. 86 ± 17 mg/dL,
P < 0.01). However, non-fasting serum glucose (277 ±
54 vs. 218 ± 14) and arterial (131 ± 8 vs. 145 ± 10 mm
Hg) pressure did not differ significantly between the
two groups. Losartan administration significantly low-
ered blood pressure (101 ± 8 mm Hg, P < 0.05) without
altering body weight (632 ± 15 g) or serum glucose con-
centration (259 ± 23) in the treated obese Zucker rats.
Expression of AT1R
In order to determine the changes of AT1R mRNA, we
performed quantitative competitive RT-PCR with AT1R
specific primers. As internal standard, we used an AT1R
deletion mutant that is coamplified with the endogenous
gene. Using the same primers for the mutant and for
the endogenous gene ensures comparable amplification
efficiencies. Each reaction was performed with a fixed
amount of AT1R wild-type cDNA and a fixed amount of
AT1R competitor cDNA. The data are expressed as the
ratio of wild-type to competitor optical densities mea-
sured by densitometric analysis. Competitive RT-PCR
data (Fig. 1A and B) showed a significant increase in
AT1R mRNA expression in the aortas of the untreated
and ARB-treated obese Zucker rats compared to that
found in the lead group.
p38 and ERK1/2 MAPK activities
The MAPK pathway has been implicated in the patho-
genesis of atherosclerosis. We therefore compared the ac-
tivation of key growth- and stress-related MAPK in the
aortas obtained from lean, untreated obese and ARB-
treated obese Zucker rats. The results (Fig. 2A and B)
showed increased activation of both p38 and ERK1/2
MAPKs, as assessed by phosphorylated kinase levels,
in the obese Zucker rat aorta compared with the lean
Zucker controls. Furthermore, these changes were sig-
nificantly attenuated by the ARB treatment.
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Fig. 2. p38 and ERK1/2 MAPK activities
in the lean Zucker rats, obese Zucker rats,
and obese Zucker rats treated with ARB
for four months. Aorta phospho-p38/p38 and
phospho-ERK1/2/ERK1/2 ratio were signifi-
cantly higher in the obese Zucker rats rela-
tive to the lean Zucker rats. Administration
of ARB significantly reduced these parame-
ters in the obese Zucker rats (A). The data
are presented as mean ± SEM from 6 rats per
group. ∗P < 0.01 vs. lean Zucker rats; +P <
0.01 vs. untreated obese Zucker rats (B).
























Fig. 3. MCP-1 and IL-6 mRNA levels in the
lean Zucker rats, obese Zucker rats, and obese
Zucker rat treated with ARB for four months.
Aorta expression levels of MCP-1 and IL-
6 mRNAs were determined by RT-PCR us-
ing 18S as internal control (A). Data are pre-
sented as mean±SEM from six rats per group.
∗P < 0.01 vs. lean; +P < 0.01 vs. obese Zucker
rats (B).
Expression of inflammatory genes, MCP-1 and IL-6
Inflammatory mediators such as MCP-1 and IL-6 have
been implicated in the pathogenesis of atherosclerosis.
We found significant up-regulation of MCP-1 and IL-6
mRNAs in the aortas of the obese Zucker rats (Fig. 3A
and B). Inflammation and fibrosis are pathologic pro-
cesses that are partially regulated by signaling through
the MAPK pathway. Since MAPK activation can increase
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Fig. 4. Collagen a1(I), FN, and PAI-1
mRNA expression in the lean Zucker rat,
obese Zucker rats, and obese Zucker rat
treated with ARB for four months. Aorta col-
lagen a1(I), FN, and PAI-1 mRNA/18S ratio
were significantly higher in the obese versus
control rats. These abnormalities were signifi-
cantly attenuated by ARB treatment for four
months in the obese Zucker rats (A). Bar
graphs represent mean ± SEM from six rats
per group. ∗P <0.01 vs. lean Zucker rats;+P <
0.05 vs. obese Zucker rats; #P < 0.05 vs. obese
Zucker rats (B).
Fig. 5. Representative photomicrographs
depicting immunohistochemical staining for
collagen IV in the aortas of a lean Zucker rat,
an obese Zucker rat, and an obese Zucker
rat treated with ARB for four months.
Compared with the lean Zucker rats (A),
collagen IV immunostaining was increased in
the aorta of obese Zucker rats (B) and was
reduced by ARB treatment (C) (×400).
the expression of inflammatory genes, we hypothesized
that the ARB-induced reduction of MAPK activation in
the obese Zucker rat may be accompanied by a parallel
reduction of MCP-1 and IL-6 expression in the aortas of
the ARB-treated obese Zucker rats. In confirmation of
this hypothesis, ARB administration was found to atten-
uate the up-regulation of MCP-1 and IL-6 in the treated
obese Zucker rats.
Fibronectin (FN), collagen, and PAI-1 expressions
FN, collagen a1(I), and PAI-1 mRNA expressions were
significantly increased in the aortas of the obese Zucker
rats relative to those in the lean controls. ARB adminis-
tration significantly attenuated the rise in FN, collagen
a1(I), and PAI-1 expressions in the obese Zucker rat
aorta (Fig. 4A and B). In agreement with the mRNA data,
immunohistologic studies of the aorta sections revealed
a significant increase in immunostainable collagen a (IV)
in the untreated obese Zucker rats that was prevented by
ARB administration (Fig. 5).
DISCUSSION
In a recent study, we found proteinuria and glomeru-
lar sclerosis, monocyte infiltration, as well as matrix
protein accumulation in the kidneys of the prediabetic
obese Zucker rats [29]. This was associated with marked
up-regulation of AT1R, MCP-1, and IL-6 expressions,
and of p38 and ERK 1/2 MAPK activities in the renal
cortex of the obese animals. Administration of AT1R
blocker, losartan, reversed elevations of MCP-1, IL-6,
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and FN expressions and MAPK activities in the kid-
neys, and prevented proteinuria and renal injury in the
obese Zucker rats. Unexpectedly, the treatment reversed
the up-regulation of AT1R expression in the kidney, as
well [29]. These observations, in part, account for in-
creased angiotensin activity and elucidate some of the
pathways involved in the pathogenesis of renal injury in
the metabolic syndrome.
As noted previously, obesity and metabolic syndrome
are associated with a high risk of arteriosclerotic cardio-
vascular disease [1, 2]. It was further noted that inflam-
mation and vascular remodeling play a central part in the
pathogenesis of atherosclerosis [7–11], and that AT1R
activation is involved in these processes [14–22, 30]. We
therefore sought to determine the effects of metabolic
syndrome and AT1R blockade on several key factors in-
volved in inflammation and vascular remodeling. Accord-
ingly, expressions of MCP-1, IL-6, PAI-1, collagen, and
FN, as well as p38 and ERK1/2 MAPK activities were in-
vestigated in the aortas obtained from the untreated and
losartan-treated obese Zucker rats prior to the onset of
frank diabetes or hypertension.
Chemokines (particularly MCP-1) and proinflamma-
tory cytokines play an important role in the activa-
tion, recruitment, and infiltration of monocytes into the
subendothelial space, where they can differentiate into
macrophages, take up lipids, and form foam cells [31]. In
addition, metalloproteinase inhibitors, specifically PAI-1,
promote matrix protein accumulation and thrombosis by
inhibiting proteolysis of matrix proteins and fibrin clot
[32]. Finally, activation of MAPK can stimulate fibrob-
last/vascular smooth muscle cell migration and prolifera-
tion. Activation of AT1R by angiotensin II can trigger all
of the above pathways in the vascular tissue and, thereby,
promote athero- and arteriosclerosis [33].
The obese Zucker rats employed in the present study
exhibited a significant increase in collagen abundance
and gene expression of matrix proteins, collagen, and
fibronectin in the aorta, pointing to occurrence of scle-
rosis and vascular remodeling. This was associated with
a marked increase in AT1R expression in the aorta. A
similar phenomenon was recently demonstrated in the
renal cortex of the obese Zucker rats exhibiting focal
glomerulosclerosis [29]. The observed up-regulation of
AT1R expression in the kidney and vascular tissues of
the obese Zucker rats points to heightened susceptibility
of these animals to angiotensin-mediated renal and vas-
cular injury and accounts for their favorable response to
angiotensin-converting enzyme inhibition and AT-1 re-
ceptor blockade [29].
Up-regulation of AT1R expression was accompanied
by a marked increase in MCP-1 mRNA in the aorta of
the obese Zucker rats. MCP-1 plays a major role in re-
cruitment of monocytes/macrophages and their infiltra-
tion in the wall of the blood vessel, an essential step
in the atherogenesis. In addition, the untreated obese
Zucker rats showed a marked up-regulation of PAI-1,
which could contribute to the observed accumulation
of collagen in their aorta. This was accompanied by
marked up-regulation of collagen and fibronectin gene
expressions in the aortas of the untreated obese Zucker
rats. Thus, increased matrix protein production and
depressed degradation (elevated tissue PAI-I) appear
to contribute to sclerosis and vascular remodeling in
metabolic syndrome. Moreover, by retarding tissue plas-
minogen activator-mediated fibrinolysis, up-regulation of
PAI-1 can contribute to the prothrombotic diathesis in
metabolic syndrome.
ERK 1/2 and p38 MAPK activities were markedly in-
creased in the aorta of the obese Zucker rats when com-
pared with their lean counterparts. This phenomenon
can contribute to migration and proliferation of vascular
smooth muscle cells and fibroblasts and, hence, vascular
remodeling in the obese Zucker rats.
Activation of AT1R by angiotensin II can potentially
trigger all of the above alterations in the vascular tissue.
This supposition is supported by the restorations of MCP-
1, IL-6, PAI-1, collagen, and FN expressions, as well as of
ERK 1/2 and p38 MAPK activities in the ARB-treated
obese Zucker rats employed in this study.
CONCLUSION
The untreated obese Zucker rats exhibited significant
up-regulations of the aorta IL-6, MCP-1, PAI-1, collagen,
fibronectin, and MAP kinase activities, pointing to activa-
tion of inflammatory cascade in the artery wall. These ab-
normalities were associated with marked up-regulation
of AT-1 receptor expression in the aorta and were pre-
vented by AT-1 receptor blockade. These observations
point to the role of AT-1 receptor activation as the likely
cause of inflammation and vascular remodeling in rats
with metabolic syndrome.
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